310 related articles for article (PubMed ID: 23323897)
21. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial.
Molina JM; Rizzardini G; Orrell C; Afani A; Calmy A; Oka S; Hinestrosa F; Kumar P; Tebas P; Walmsley S; Grandhi A; Klopfer S; Gendrano I; Eves K; Correll TA; Fox MC; Kim J
Lancet HIV; 2024 Jun; 11(6):e369-e379. PubMed ID: 38734015
[TBL] [Abstract][Full Text] [Related]
22. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.
Sterling TR; Vlahov D; Astemborski J; Hoover DR; Margolick JB; Quinn TC
N Engl J Med; 2001 Mar; 344(10):720-5. PubMed ID: 11236775
[TBL] [Abstract][Full Text] [Related]
23. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection.
Paton NI; Stöhr W; Oddershede L; Arenas-Pinto A; Walker S; Sculpher M; Dunn DT
Health Technol Assess; 2016 Mar; 20(21):1-158. PubMed ID: 26986803
[TBL] [Abstract][Full Text] [Related]
24. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.
Lawrence J; Mayers DL; Hullsiek KH; Collins G; Abrams DI; Reisler RB; Crane LR; Schmetter BS; Dionne TJ; Saldanha JM; Jones MC; Baxter JD;
N Engl J Med; 2003 Aug; 349(9):837-46. PubMed ID: 12944569
[TBL] [Abstract][Full Text] [Related]
25. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.
Grinsztejn B; Hosseinipour MC; Ribaudo HJ; Swindells S; Eron J; Chen YQ; Wang L; Ou SS; Anderson M; McCauley M; Gamble T; Kumarasamy N; Hakim JG; Kumwenda J; Pilotto JH; Godbole SV; Chariyalertsak S; de Melo MG; Mayer KH; Eshleman SH; Piwowar-Manning E; Makhema J; Mills LA; Panchia R; Sanne I; Gallant J; Hoffman I; Taha TE; Nielsen-Saines K; Celentano D; Essex M; Havlir D; Cohen MS;
Lancet Infect Dis; 2014 Apr; 14(4):281-90. PubMed ID: 24602844
[TBL] [Abstract][Full Text] [Related]
26. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
Swindells S; Andrade-Villanueva JF; Richmond GJ; Rizzardini G; Baumgarten A; Masiá M; Latiff G; Pokrovsky V; Bredeek F; Smith G; Cahn P; Kim YS; Ford SL; Talarico CL; Patel P; Chounta V; Crauwels H; Parys W; Vanveggel S; Mrus J; Huang J; Harrington CM; Hudson KJ; Margolis DA; Smith KY; Williams PE; Spreen WR
N Engl J Med; 2020 Mar; 382(12):1112-1123. PubMed ID: 32130809
[TBL] [Abstract][Full Text] [Related]
27. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Overton ET; Girard PM; Oka S; Walmsley S; Bettacchi C; Brinson C; Philibert P; Lombaard J; St Clair M; Crauwels H; Ford SL; Patel P; Chounta V; D'Amico R; Vanveggel S; Dorey D; Cutrell A; Griffith S; Margolis DA; Williams PE; Parys W; Smith KY; Spreen WR
N Engl J Med; 2020 Mar; 382(12):1124-1135. PubMed ID: 32130806
[TBL] [Abstract][Full Text] [Related]
28. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.
Mfinanga SG; Kirenga BJ; Chanda DM; Mutayoba B; Mthiyane T; Yimer G; Ezechi O; Connolly C; Kapotwe V; Muwonge C; Massaga J; Sinkala E; Kohi W; Lyantumba L; Nyakoojo G; Luwaga H; Doulla B; Mzyece J; Kapata N; Vahedi M; Mwaba P; Egwaga S; Adatu F; Pym A; Joloba M; Rustomjee R; Zumla A; Onyebujoh P
Lancet Infect Dis; 2014 Jul; 14(7):563-71. PubMed ID: 24810491
[TBL] [Abstract][Full Text] [Related]
29. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
30. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
31. Maraviroc for previously treated patients with R5 HIV-1 infection.
Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
[TBL] [Abstract][Full Text] [Related]
32. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.
Babiker AG; Emery S; Fätkenheuer G; Gordin FM; Grund B; Lundgren JD; Neaton JD; Pett SL; Phillips A; Touloumi G; Vjechaj MJ;
Clin Trials; 2013; 10(1 Suppl):S5-S36. PubMed ID: 22547421
[TBL] [Abstract][Full Text] [Related]
33. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.
Cotton MF; Violari A; Otwombe K; Panchia R; Dobbels E; Rabie H; Josipovic D; Liberty A; Lazarus E; Innes S; van Rensburg AJ; Pelser W; Truter H; Madhi SA; Handelsman E; Jean-Philippe P; McIntyre JA; Gibb DM; Babiker AG;
Lancet; 2013 Nov; 382(9904):1555-63. PubMed ID: 24209829
[TBL] [Abstract][Full Text] [Related]
34. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Thongyen S; Likanonsakul S; Suwanvattana P; Thawornwan U; Suntisuklappon B; Nilkamhang S; Sungkanuparph S;
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):377-83. PubMed ID: 22592586
[TBL] [Abstract][Full Text] [Related]
35. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
; Mugyenyi P; Walker AS; Hakim J; Munderi P; Gibb DM; Kityo C; Reid A; Grosskurth H; Darbyshire JH; Ssali F; Bray D; Katabira E; Babiker AG; Gilks CF; Grosskurth H; Munderi P; Kabuye G; Nsibambi D; Kasirye R; Zalwango E; Nakazibwe M; Kikaire B; Nassuna G; Massa R; Fadhiru K; Namyalo M; Zalwango A; Generous L; Khauka P; Rutikarayo N; Nakahima W; Mugisha A; Todd J; Levin J; Muyingo S; Ruberantwari A; Kaleebu P; Yirrell D; Ndembi N; Lyagoba F; Hughes P; Aber M; Lara AM; Foster S; Amurwon J; Wakholi BN; Whitworth J; Wangati K; Amuron B; Kajungu D; Nakiyingi J; Omony W; Fadhiru K; Nsibambi D; Khauka P; Mugyenyi P; Kityo C; Ssali F; Tumukunde D; Otim T; Kabanda J; Musana H; Akao J; Kyomugisha H; Byamukama A; Sabiiti J; Komugyena J; Wavamunno P; Mukiibi S; Drasiku A; Byaruhanga R; Labeja O; Katundu P; Tugume S; Awio P; Namazzi A; Bakeinyaga GT; Katabira H; Abaine D; Tukamushaba J; Anywar W; Ojiambo W; Angweng E; Murungi S; Haguma W; Atwiine S; Kigozi J; Namale L; Mukose A; Mulindwa G; Atwiine D; Muhwezi A; Nimwesiga E; Barungi G; Takubwa J; Murungi S; Mwebesa D; Kagina G; Mulindwa M; Ahimbisibwe F; Mwesigwa P; Akuma S; Zawedde C; Nyiraguhirwa D; Tumusiime C; Bagaya L; Namara W; Kigozi J; Karungi J; Kankunda R; Enzama R; Latif A; Hakim J; Robertson V; Reid A; Chidziva E; Bulaya-Tembo R; Musoro G; Taziwa F; Chimbetete C; Chakonza L; Mawora A; Muvirimi C; Tinago G; Svovanapasis P; Simango M; Chirema O; Machingura J; Mutsai S; Phiri M; Bafana T; Chirara M; Muchabaiwa L; Muzambi M; Mutowo J; Chivhunga T; Chigwedere E; Pascoe M; Warambwa C; Zengeza E; Mapinge F; Makota S; Jamu A; Ngorima N; Chirairo H; Chitsungo S; Chimanzi J; Maweni C; Warara R; Matongo M; Mudzingwa S; Jangano M; Moyo K; Vere L; Mdege N; Machingura I; Katabira E; Ronald A; Kambungu A; Lutwama F; Mambule I; Nanfuka A; Walusimbi J; Nabankema E; Nalumenya R; Namuli T; Kulume R; Namata I; Nyachwo L; Florence A; Kusiima A; Lubwama E; Nairuba R; Oketta F; Buluma E; Waita R; Ojiambo H; Sadik F; Wanyama J; Nabongo P; Oyugi J; Sematala F; Muganzi A; Twijukye C; Byakwaga H; Ochai R; Muhweezi D; Coutinho A; Etukoit B; Gilks C; Boocock K; Puddephatt C; Grundy C; Bohannon J; Winogron D; Gibb DM; Burke A; Bray D; Babiker A; Walker AS; Wilkes H; Rauchenberger M; Sheehan S; Spencer-Drake C; Taylor K; Spyer M; Ferrier A; Naidoo B; Dunn D; Goodall R; Darbyshire JH; Peto L; Nanfuka R; Mufuka-Kapuya C; Kaleebu P; Pillay D; Robertson V; Yirrell D; Tugume S; Chirara M; Katundu P; Ndembi N; Lyagoba F; Dunn D; Goodall R; McCormick A; Lara AM; Foster S; Amurwon J; Wakholi BN; Kigozi J; Muchabaiwa L; Muzambi M; Weller I; Babiker A; Bahendeka S; Bassett M; Wapakhabulo AC; Darbyshire JH; Gazzard B; Gilks C; Grosskurth H; Hakim J; Latif A; Mapuchere C; Mugurungi O; Mugyenyi P; Burke C; Jones S; Newland C; Pearce G; Rahim S; Rooney J; Smith M; Snowden W; Steens JM; Breckenridge A; McLaren A; Hill C; Matenga J; Pozniak A; Serwadda D; Peto T; Palfreeman A; Borok M; Katabira E
Lancet; 2010 Jan; 375(9709):123-31. PubMed ID: 20004464
[TBL] [Abstract][Full Text] [Related]
36. Antiretroviral Therapy for the Prevention of HIV-1 Transmission.
Cohen MS; Chen YQ; McCauley M; Gamble T; Hosseinipour MC; Kumarasamy N; Hakim JG; Kumwenda J; Grinsztejn B; Pilotto JH; Godbole SV; Chariyalertsak S; Santos BR; Mayer KH; Hoffman IF; Eshleman SH; Piwowar-Manning E; Cottle L; Zhang XC; Makhema J; Mills LA; Panchia R; Faesen S; Eron J; Gallant J; Havlir D; Swindells S; Elharrar V; Burns D; Taha TE; Nielsen-Saines K; Celentano DD; Essex M; Hudelson SE; Redd AD; Fleming TR;
N Engl J Med; 2016 Sep; 375(9):830-9. PubMed ID: 27424812
[TBL] [Abstract][Full Text] [Related]
37. Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial.
Mallewa J; Szubert AJ; Mugyenyi P; Chidziva E; Thomason MJ; Chepkorir P; Abongomera G; Baleeta K; Etyang A; Warambwa C; Melly B; Mudzingwa S; Kelly C; Agutu C; Wilkes H; Nkomani S; Musiime V; Lugemwa A; Pett SL; Bwakura-Dangarembizi M; Prendergast AJ; Gibb DM; Walker AS; Berkley JA;
Lancet HIV; 2018 May; 5(5):e231-e240. PubMed ID: 29653915
[TBL] [Abstract][Full Text] [Related]
38. Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial.
de Truchis P; Assoumou L; Landman R; Mathez D; Le Dû D; Bellet J; Amat K; Katlama C; Gras G; Bouchaud O; Duracinsky M; Abe E; Alvarez JC; Izopet J; Saillard J; Melchior JC; Leibowitch J; Costagliola D; Girard PM; Perronne C;
J Antimicrob Chemother; 2018 Mar; 73(3):738-747. PubMed ID: 29186458
[TBL] [Abstract][Full Text] [Related]
39. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.
Zolopa A; Andersen J; Powderly W; Sanchez A; Sanne I; Suckow C; Hogg E; Komarow L
PLoS One; 2009; 4(5):e5575. PubMed ID: 19440326
[TBL] [Abstract][Full Text] [Related]
40. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS.
Meintjes G; Stek C; Blumenthal L; Thienemann F; Schutz C; Buyze J; Ravinetto R; van Loen H; Nair A; Jackson A; Colebunders R; Maartens G; Wilkinson RJ; Lynen L;
N Engl J Med; 2018 Nov; 379(20):1915-1925. PubMed ID: 30428290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
